In both BC cell lines, the DEA treatment increased the steady-state level of fusion-associated protein optic atrophy 1 (OPA1), but it decreased mitofusin (Mfn) 1 and 2 in 4T1 cells (Figure 6B). This evidence concerns the gene OPA1 and breast cancer.